Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis
Launched by ULTHERA, INC · Oct 22, 2012
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
Subjects will be randomized to one of two study groups:
* Group A: Split body treatment. Ultherapy to one axilla, Sham treatment to the other axilla.
* Group B: Bilateral Ultherapy treatments, with a pre-treatment subcutaneous lidocaine injection administered to one axillary side.
Hyperhidrosis Disease Severity Scale (HDSS), gravimetric test and starch iodine test will be obtained at all study visits. Patient satisfaction questionnaires will also be obtained at 30, 60 and 90 days post-treatment #2.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female, ages 18-75
- • Subject is in good health
- • Diagnosis of bilateral axillary hyperhidrosis refractory to previous topical therapies
- • At least 50 mg of spontaneous resting axillary sweat production in each axilla measured gravimetrically at room temperature/humidity (20 - 25.6°C/20-80%) over a period of 5 minutes. (Patients should be at rest for at least 30 minutes after physical exercise including walking.)
- • HDSS score of 3 or 4.
- • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
- Exclusion Criteria:
- • Dermal disorder including infection at anticipated treatment sites in either axilla.
- • Previous botulinum toxin treatment of the axilla in the past year.
- • Expected use of botulinum toxin for the treatment of any other disease during the study period.
- • Known allergy to starch powder or iodine.
- • Secondary hyperhidrosis, for example, hyperhidrosis that is secondary to other underlying diseases including hyperthyroidism, lymphoma and malaria.
- • Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage and ultrasonic surgery.
- • Women who are pregnant, lactating, possibly pregnant or planning a pregnancy during the study period.
About Ulthera, Inc
Ulthera, Inc. is a leading medical technology company specializing in non-invasive ultrasound solutions for aesthetic and therapeutic applications. Committed to advancing patient care through innovative research and development, Ulthera focuses on delivering safe and effective treatments that enhance skin lifting and tightening. The company’s flagship product, the Ultherapy system, utilizes ultrasound energy to stimulate collagen production and improve skin elasticity. By partnering with clinical researchers and practitioners, Ulthera aims to expand the understanding of ultrasound technology in dermatology and cosmetic procedures, ensuring high standards of safety and efficacy in all its offerings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aventura, Florida, United States
Patients applied
Trial Officials
Mark Nestor, MD, Ph.D
Principal Investigator
The Center for Clinical & Cosmetic Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials